N-叔丁基-2-(4-甲酰基苯基)苯磺酰胺 | 851902-28-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-叔丁基-2-(4-甲酰基苯基)苯磺酰胺
• 英文名称: 4'-formylbiphenyl-2-sulfonic acid t-butylamide
• 英文别名: N-tert-butyl-4'-formylbiphenyl-2-sulfonamide；N-tert-butyl-2-(4-formylphenyl)benzenesulfonamide
• CAS: 851902-28-8
• 化学式: C₁₇H₁₉NO₃S
• 分子量: 317.409
• InChiKey: XONKDEIZWYZWON-UHFFFAOYSA-N

物化性质

• 沸点：
  489.8±55.0 °C(Predicted)
• 密度：
  1.190±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-叔丁基-2-(4-甲酰基苯基)苯磺酰胺 在 palladium on activated charcoal 氢气 、 羟胺 、 sodium carbonate 、 N,N'-羰基二咪唑 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 50.0 ℃ 、344.74 kPa 条件下， 生成 trans-1-(RS)-[4-(2-aminosulfonylphenyl)]-benzylaminocarbonyl-2-(SR)-carboxycyclopentane
  参考文献：
  名称：

  Novel cyclopentane dicarboxamide sodium channel blockers as a potential treatment for chronic pain

  摘要：

  A series of new voltage-gated sodium channel blockers were prepared based on the screening lead succinic diamide BPBTS. Replacement of the succinimide linker with the more rigid cyclic 1,2-trans-diamide linker was well tolerated. N-Methylation on the biphenylsulfonamide side of the amide moiety significantly reduced the clearance rate in rat pharmacokinetic studies. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.02.002
• 作为产物：
  描述：

  4-甲酰基苯硼酸 、 2-溴-N-叔丁基苯磺酰胺 在 四(三苯基膦)钯 potassium carbonate 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 生成 N-叔丁基-2-(4-甲酰基苯基)苯磺酰胺
  参考文献：
  名称：

  Dual-acting antihypertensive agents

  摘要：

  该发明涉及以下化合物的公式I：其中Ar、r、R3、X和R5-7如规范中定义，并且其药用盐。公式I的化合物具有AT1受体拮抗活性和脑利钠酶抑制活性。该发明还涉及包含这种化合物的药物组合物；使用这种化合物的方法；以及制备这种化合物的过程和中间体。

  公开号：

  US20080188533A1

文献信息

• [EN] DUAL-ACTING ANTIHYPERTENSIVE AGENTS<br/>[FR] AGENTS ANTIHYPERTENSIFS À DOUBLE ACTION
  申请人：THERAVANCE INC

  公开号：WO2009035543A1

  公开（公告）日：2009-03-19

  The invention relates to compounds having the formula: (I) wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  本发明涉及具有以下公式的化合物：(I) 其中：Ar、r、R3、Z、X和R5-7按说明书定义，或其药用可接受盐。这些化合物具有AT1受体拮抗活性和中性内肽酶抑制活性。本发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• Dual-acting benzoimidazole antihypertensive agents
  申请人：Allegretti Paul

  公开号：US20080318951A1

  公开（公告）日：2008-12-25

  The invention is directed to compounds having the formula: wherein: Ar, r, n, X, R 2-3 and R 5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  这项发明涉及具有以下结构的化合物： 其中：Ar、r、n、X、R 2-3 和R 5-7 如规范中所定义，并且其药学上可接受的盐。这些化合物具有AT 1 受体拮抗活性和神经肽酶抑制活性。该发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• Dual-acting antihypertensive agents
  申请人：Allegretti Paul

  公开号：US20080269305A1

  公开（公告）日：2008-10-30

  The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R 5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  该发明涉及具有以下公式的化合物：其中：Ar、r、Y、Z、Q、W、X和R5-7如规范中定义，并且其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和神经肽酶抑制活性。该发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• DUAL-ACTING ANTIHYPERTENSIVE AGENTS
  申请人：CHOI Seok-Ki

  公开号：US20100022599A1

  公开（公告）日：2010-01-28

  In one aspect, the invention relates to compounds having the formula: wherein: Ar, r, Z, X, R 3 , and R 5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  在一个方面，该发明涉及具有以下结构的化合物：其中：Ar、r、Z、X、R3和R5-7如规范中定义，或其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和脑利钠酶抑制活性。在另一个方面，该发明涉及包含此类化合物的药物组合物；使用这类化合物的方法；以及用于制备这类化合物的工艺和中间体。
• DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS
  申请人：Choi Seok-Ki

  公开号：US20090149521A1

  公开（公告）日：2009-06-11

  The invention relates to compounds having the formula: wherein Ar, r, n, X, R 2 , R 2′ , R 3 , and R 5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.

  这项发明涉及具有以下结构的化合物：其中Ar、r、n、X、R2、R2'、R3和R5-7的定义如规范中所述，或其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和脑利钠酶抑制活性。该发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。